Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) Shares Purchased by Keybank National Association OH

Keybank National Association OH increased its position in shares of Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) by 41.4% in the 4th quarter, according to the company in its most recent disclosure with the SEC. The fund owned 25,512 shares of the company’s stock after purchasing an additional 7,469 shares during the quarter. Keybank National Association OH’s holdings in Phathom Pharmaceuticals were worth $207,000 as of its most recent filing with the SEC.

Several other hedge funds and other institutional investors have also recently bought and sold shares of the company. Jennison Associates LLC raised its holdings in shares of Phathom Pharmaceuticals by 20.4% in the fourth quarter. Jennison Associates LLC now owns 7,062,507 shares of the company’s stock worth $57,348,000 after acquiring an additional 1,196,118 shares during the last quarter. Portolan Capital Management LLC raised its holdings in shares of Phathom Pharmaceuticals by 50.4% in the third quarter. Portolan Capital Management LLC now owns 1,699,918 shares of the company’s stock worth $30,735,000 after acquiring an additional 569,829 shares during the last quarter. Checkpoint Capital L.P. raised its holdings in shares of Phathom Pharmaceuticals by 71.9% in the third quarter. Checkpoint Capital L.P. now owns 1,504,307 shares of the company’s stock worth $27,198,000 after acquiring an additional 629,307 shares during the last quarter. FMR LLC raised its holdings in shares of Phathom Pharmaceuticals by 49,000.7% in the third quarter. FMR LLC now owns 1,304,114 shares of the company’s stock worth $23,578,000 after acquiring an additional 1,301,458 shares during the last quarter. Finally, State Street Corp raised its holdings in shares of Phathom Pharmaceuticals by 17.5% in the third quarter. State Street Corp now owns 922,788 shares of the company’s stock worth $16,684,000 after acquiring an additional 137,539 shares during the last quarter. 99.01% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling at Phathom Pharmaceuticals

In other Phathom Pharmaceuticals news, insider Terrie Curran sold 19,109 shares of the business’s stock in a transaction dated Tuesday, January 21st. The stock was sold at an average price of $6.59, for a total transaction of $125,928.31. Following the completion of the sale, the insider now owns 360,465 shares of the company’s stock, valued at approximately $2,375,464.35. The trade was a 5.03 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CFO Molly Henderson sold 6,583 shares of the company’s stock in a transaction dated Tuesday, January 21st. The stock was sold at an average price of $6.59, for a total value of $43,381.97. Following the completion of the sale, the chief financial officer now directly owns 93,546 shares of the company’s stock, valued at $616,468.14. The trade was a 6.57 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 35,987 shares of company stock valued at $240,551. Company insiders own 24.10% of the company’s stock.

Phathom Pharmaceuticals Trading Up 8.9 %

PHAT stock opened at $4.79 on Wednesday. The stock has a 50-day moving average price of $6.21 and a two-hundred day moving average price of $11.10. Phathom Pharmaceuticals, Inc. has a 12-month low of $4.33 and a 12-month high of $19.71. The company has a market cap of $327.53 million, a PE ratio of -0.84 and a beta of 0.63.

Analyst Ratings Changes

PHAT has been the subject of a number of analyst reports. Needham & Company LLC reissued a “buy” rating and issued a $28.00 price target on shares of Phathom Pharmaceuticals in a report on Thursday, March 6th. Craig Hallum reiterated a “buy” rating on shares of Phathom Pharmaceuticals in a research note on Friday. HC Wainwright reiterated a “buy” rating and issued a $28.00 target price on shares of Phathom Pharmaceuticals in a research note on Friday, March 7th. Guggenheim set a $18.00 target price on Phathom Pharmaceuticals in a research note on Friday. Finally, The Goldman Sachs Group dropped their target price on Phathom Pharmaceuticals from $18.00 to $12.00 and set a “neutral” rating for the company in a research note on Monday. One analyst has rated the stock with a hold rating, four have given a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat, the company presently has a consensus rating of “Buy” and an average target price of $22.17.

Phathom Pharmaceuticals Company Profile

Phathom Pharmaceuticals, Inc, biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada for an investigational potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach.